litlas
ログインアカウント作成

Emily Chan

1994–2026 年に発表

130
論文数
21,968
被引用数
66
h 指数
113
i10 指数

被引用数

Emily Chan の年別被引用数1994 年: 被引用 1 件1995 年: 被引用 2 件1996 年: 被引用 3 件1997 年: 被引用 4 件1998 年: 被引用 2 件1999 年: 被引用 7 件2000 年: 被引用 3 件2001 年: 被引用 2 件2002 年: 被引用 7 件2003 年: 被引用 33 件2004 年: 被引用 33 件2005 年: 被引用 33 件2006 年: 被引用 82 件2007 年: 被引用 88 件2008 年: 被引用 120 件2009 年: 被引用 139 件2010 年: 被引用 116 件2011 年: 被引用 113 件2012 年: 被引用 104 件2013 年: 被引用 202 件2014 年: 被引用 182 件2015 年: 被引用 227 件2016 年: 被引用 232 件2017 年: 被引用 333 件2018 年: 被引用 276 件2019 年: 被引用 848 件2020 年: 被引用 833 件2021 年: 被引用 738 件2022 年: 被引用 582 件2023 年: 被引用 449 件2024 年: 被引用 841 件2025 年: 被引用 487 件2026 年: 被引用 18 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,113 件、この内訳の 28.1%中国: 引用元論文 1,098 件、この内訳の 9.9%イタリア: 引用元論文 671 件、この内訳の 6.1%イギリス: 引用元論文 596 件、この内訳の 5.4%ドイツ: 引用元論文 560 件、この内訳の 5%フランス: 引用元論文 516 件、この内訳の 4.7%スペイン: 引用元論文 401 件、この内訳の 3.6%日本: 引用元論文 360 件、この内訳の 3.2%カナダ: 引用元論文 329 件、この内訳の 3%オランダ: 引用元論文 316 件、この内訳の 2.8%オーストラリア: 引用元論文 287 件、この内訳の 2.6%スイス: 引用元論文 256 件、この内訳の 2.3%
0%28.1%その他 23.3%

機関

分野

  • Medicine58%
  • Biochemistry, Genetics and Molecular Biology30.7%
  • Immunology and Microbiology3.5%
  • Computer Science1.7%
  • Neuroscience1.3%
  • Nursing0.7%
  • その他4.1%

トピック

  • Colorectal Cancer Treatments and Studies4%
  • Cancer Genomics and Diagnostics3%
  • Cancer Immunotherapy and Biomarkers2.9%
  • Lung Cancer Treatments and Mutations2.6%
  • Melanoma and MAPK Pathways2.1%
  • Colorectal Cancer Surgical Treatments1.9%
  • その他83.5%

共著者

全論文

検索で開く
  1. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

    著者: Marwan Fakih, Lisa Salvatore, Taito Esaki, Dominik Paul Modest, D. Páez López-Bravo, Julien Taı̈eb, Michalis V. Karamouzis, Erika Ruíz‐García, Tae‐Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun‐Huei Yeh, Emily Chan, Joseph Chao, Yaneth Saportas, Qui Tran, Chiara Cremolini, Filippo Pietrantonio - New England Journal of Medicine 2023 被引用: 342

  2. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    著者: David M. Hyman, Igor Puzanov, Vivek Subbiah, Jason E. Faris, Ian Chau, Jean‐Yves Blay, Jürgen Wolf, Noopur Raje, Eli L. Diamond, Antoine Hollebecque, Radj Gervais, Maria Elena Elez-Fernandez, Antoîne Italiano, Ralf‐Dieter Hofheinz, Manuel Hidalgo, Emily Chan, Martin Schüler, Susan Frances Lasserre, Martina Makrutzki, Florin Sirzén, Maria Luisa Veronese, Josep Tabernero, José Baselga - New England Journal of Medicine 2015 被引用: 1,734

  3. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance

    著者: Thijs J. Hagenbeek, Jason R. Zbieg, Marc Hafner, Rana Mroue, Jennifer A. Lacap, Nicole M. Sodir, Cameron L. Noland, Shervin Afghani, Ayush Kishore, Kamakoti P. Bhat, Xiaosai Yao, Stephen D. Schmidt, Saundra Clausen, Micah Steffek, Wendy Lee, Paul Beroza, Scott E. Martin, Eva Lin, Rina Fong, Paola Di Lello, Marta H. Kubala, Michelle N.-Y. Yang, Jeffrey Lau, Emily Chan, Alfonso Arrazate, Le An, Elizabeth Levy, Maria Lorenzo, Ho-June Lee, Trang H. Pham, Zora Modrušan, Richard Zang, Yi‐Chen Chen, Michał Kabza, Musaddeque Ahmed, Jason Li, Matthew T. Chang, Danilo Maddalo, Marie Evangelista, Xin Ye, James J. Crawford, Anwesha Dey - Nature Cancer 2023 被引用: 195

  4. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer

    著者: Julien Dilly, Megan T. Hoffman, Laleh Abbassi, Ziyue Li, Francesca Paradiso, Brendan D. Parent, Connor J. Hennessey, Alexander C. Jordan, Micaela Morgado, Shatavisha Dasgupta, Giselle A. Uribe, Annan Yang, Kevin S. Kapner, Felix P. Hambitzer, Qiang Li, Hanrong Feng, Jacob Geisberg, Junning Wang, Kyle E. Evans, Hengyu Lyu, Aislyn Schalck, Ningping Feng, Anastasia M. Lopez, Christopher A. Bristow, Michael P. Kim, Kimal Rajapakshe, Vahid Bahrambeigi, Jennifer A. Roth, Kavita S. Garg, Paola A. Guerrero, Ben Z. Stanger, Simona Cristea, Scott W. Lowe, Timour Baslan, Eliezer M. Van Allen, Joseph D. Mancias, Emily Chan, Abraham Anderson, Yuliya V. Katlinskaya, Alex K. Shalek, David S. Hong, Shubham Pant, Jill Hallin, Kenna Anderes, Peter Olson, Timothy P. Heffernan, Seema Chugh, James G. Christensen, Anirban Maitra, Brian M. Wolpin, Srivatsan Raghavan, Jonathan A. Nowak, Peter Winter, Stephanie K. Dougan, Andrew J. Aguirre - Cancer Discovery 2024 被引用: 234

  5. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers

    著者: Jennifer Cantley, Xiaofen Ye, Emma Rousseau, Tom Januario, Brian D. Hamman, Christopher M. Rose, Tommy K. Cheung, Trent Hinkle, Leofal Soto, Connor Quinn, Alicia Harbin, Elizabeth Bortolon, Xin Chen, Roy Haskell, Eva Lin, Shang‐Fan Yu, Geoff Del Rosario, Emily Chan, Debra Dunlap, Hartmut Koeppen, Scott E. Martin, Mark Merchant, Matthew Grimmer, Fabio Broccatelli, Jing Wang, Jennifer Pizzano, Peter S. Dragovich, Michael Berlin, Robert L. Yauch - Nature Communications 2022 被引用: 129

  6. Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

    著者: Christine H. Chung, Beloo Mirakhur, Emily Chan, Quynh‐Thu Le, Jordan Berlin, Michael A. Morse, Barbara A. Murphy, Shama M. Satinover, Jacob D. Hosen, David Mauro, Robbert J.C. Slebos, Qinwei Zhou, Diane R. Gold, Tina Hatley, Daniel J. Hicklin, Thomas A.E. Platts‐Mills - New England Journal of Medicine 2008 被引用: 1,483

  7. Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation

    著者: Ryan Raisner, Samir Kharbanda, Lingyan Jin, Edwin E. Jeng, Emily Chan, Mark Merchant, Peter M. Haverty, Russell Bainer, Tommy K. Cheung, David Arnott, E. Megan Flynn, F. Anthony Romero, Steven Magnuson, Karen E. Gascoigne - Cell Reports 2018 被引用: 415

  8. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer

    著者: Scott Kopetz, Jayesh Desai, Emily Chan, J. Randolph Hecht, Peter J. O’Dwyer, Dipen M. Maru, Van K. Morris, Filip Jankú, Arvind Dasari, Woonbok Chung, Jean‐Pierre J. Issa, Peter Gibbs, Brian P. James, Garth Powis, K. B. Nolop, Suman Bhattacharya, Leonard B. Saltz - Journal of Clinical Oncology 2015 被引用: 693

  9. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial

    著者: Reinhard Dummer, David Gyorki, John Hyngstrom, Adam C. Berger, Robert M. Conry, Lev Demidov, Anjali Sharma, Sheryl Treichel, Hoi-Shen Radcliffe, Kevin Gorski, Abraham Anderson, Emily Chan, Mark B. Faries, Merrick I. Ross - Nature Medicine 2021 被引用: 148

  10. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

    著者: Yasutoshi Kuboki, Marwan Fakih, John H. Strickler, Rona Yaeger, Toshiki Masuishi, Edward Kim, Christine M. Bestvina, Scott Kopetz, Gerald S. Falchook, Corey J. Langer, John C. Krauss, Sonam Puri, Panli Cardona, Emily Chan, Tracy Varrieur, Lata Mukundan, Abraham Anderson, Qui Tran, David S. Hong - Nature Medicine 2024 被引用: 89

  11. Towards a Framework for Teaching Debugging

    著者: Chen Li, Emily Chan, Paul Denny, Andrew Luxton-Reilly, Ewan D. Tempero - Twenty-First Australasian Computing Education Conference, ACE 2019 被引用: 62

  12. Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer

    著者: Lingyan Jin, Jesse Garcia, Emily Chan, Cecile de la Cruz, Ehud Segal, Mark Merchant, Samir Kharbanda, Ryan Raisner, Peter M. Haverty, Zora Modrušan, Justin Q. Ly, Edna F. Choo, Susan Kaufman, Maureen H. Beresini, F. Anthony Romero, Steven Magnuson, Karen E. Gascoigne - Cancer Research 2017 被引用: 152

  13. GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP)

    著者: F. Anthony Romero, Jeremy Murray, Kwong Wah Lai, Vickie Tsui, Brian K. Albrecht, Le An, Maureen H. Beresini, Gladys de Leon Boenig, Sarah M. Bronner, Emily Chan, Kevin X. Chen, Zhongguo Chen, Edna F. Choo, Kyle Clagg, Kevin Clark, Terry D. Crawford, Patrick Cyr, Denise de Almeida Nagata, Karen E. Gascoigne, Jane L. Grogan, Georgia Hatzivassiliou, Wei Huang, Thomas Hunsaker, Susan Kaufman, Stefan G. Koenig, Ruina Li, Yingjie Li, Xiaorong Liang, Jiangpeng Liao, Wenfeng Liu, Justin Q. Ly, Jonathan Maher, Colin Masui, Mark Merchant, Yingqing Ran, Alexander M. Taylor, John Wai, Fei Wang, Xiaocang Wei, Dong Yu, Bing‐Yan Zhu, Xiaoyu Zhu, Steven Magnuson - Journal of Medicinal Chemistry 2017 被引用: 131

  14. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

    著者: Al B. Benson, Alan P. Venook, Lynette Cederquist, Emily Chan, Yi‐Jen Chen, Harry S. Cooper, Dustin A. Deming, Paul F. Engstrom, Peter C. Enzinger, Alessandro Fichera, Jean L. Grem, Axel Grothey, Howard S. Höchster, Sarah E. Hoffe, Steven R. Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard B. Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky‐Himelfarb, Christopher G. Willett, Christina Wu, Kristina M. Gregory, Deborah A. Freedman-Cass - Journal of the National Comprehensive Cancer Network 2017 被引用: 1,371

  15. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells

    著者: Jonathan Chou, Kai Trepka, Martin Sjöström, Emily A. Egusa, Carissa Chu, Jun Zhu, Emily Chan, Ewan A. Gibb, Michelle L. Badura, Alberto Contreras‐Sanz, Bradley A. Stohr, Maxwell V. Meng, Raj S. Pruthi, Yair Lotan, Peter C. Black, Sima P. Porten, Vadim S. Koshkin, Terence W. Friedlander, Felix Y. Feng - European Urology Oncology 2022 被引用: 86

  16. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

    著者: Timothy R. Wilson, Jane Fridlyand, Yibing Yan, Elicia Penuel, Luciana Burton, Emily Chan, Jing Peng, Eva Lin, Yulei Wang, Jeff Sosman, Antoni Ribas, Li Jiang, John G. Moffat, Daniel P. Sutherlin, Hartmut Koeppen, Mark Merchant, Richard M. Neve, Jeff Settleman - Nature 2012 被引用: 1,121

  17. Covalent Proteins as Targeted Radionuclide Therapies Enhance Antitumor Effects

    著者: Paul C. Klauser, Shalini Chopra, Li Cao, Kondapa Naidu Bobba, Bingchen Yu, Youngho Seo, Emily Chan, Robert R. Flavell, Michael J. Evans, Lei Wang - ACS Central Science 2023 被引用: 56

  18. Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation

    著者: Denise E. de Almeida Nagata, Eugene Y. Chiang, Suchit Jhunjhunwala, Patrick Caplazi, Vidhyalakshmi Arumugam, Zora Modrušan, Emily Chan, Mark Merchant, Lingyan Jin, David Arnott, F. Anthony Romero, Steven Magnuson, Karen E. Gascoigne, Jane L. Grogan - Cell Reports 2019 被引用: 72

  19. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

    著者: Jonathan Chou, Emily A. Egusa, Sinan Wang, Michelle L. Badura, Fei Lee, Anil P. Bidkar, Jun Zhu, Tanushree Shenoy, Kai Trepka, Troy M. Robinson, Veronica Steri, Jiaoti Huang, Yuzhuo Wang, Eric J. Small, Emily Chan, Bradley A. Stohr, Alan Ashworth, Brant Delafontaine, Sylvie Rottey, Keegan S. Cooke, Nooshin Hashemi Sadraei, Brian Yu, Mark Salvati, Julie M. Bailis, Felix Y. Feng, Robert R. Flavell, Rahul Aggarwal - Cancer Research 2022 被引用: 60

  20. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy

    著者: Anil P. Bidkar, Sinan Wang, Kondapa Naidu Bobba, Emily Chan, Scott Bidlingmaier, Emily A. Egusa, Robin Peter, Umama Ali, Niranjan Meher, Anju Wadhwa, Suchi Dhrona, Chandrashekhar Dasari, Denis Beckford-Vera, Yang Su, Ryan Tang, Li Zhang, Jiang He, David M. Wilson, Rahul Aggarwal, Henry F. VanBrocklin, Youngho Seo, Jonathan Chou, Bin Liu, Robert R. Flavell - Clinical Cancer Research 2023 被引用: 49

  21. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

    著者: Padmanee Sharma, Margaret K. Callahan, Petri Bono, Joseph W. Kim, Pavlina Spiliopoulou, Emiliano Calvo, Rathi N. Pillai, Patrick A. Ott, Filippo de Braud, Michael A. Morse, Dung T. Le, Dirk Jaeger, Emily Chan, Chris Harbison, Chen-Sheng Lin, Marina Tschaika, Alex Azrilevich, Jonathan E. Rosenberg - The Lancet Oncology 2016 被引用: 685

  22. A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

    著者: Anthony W. Tolcher, Jordan Berlin, Jan Cosaert, John Kauh, Emily Chan, Sarina A. Piha‐Paul, Alex Amaya, Shande Tang, Kyla Driscoll, Richard Kimbung, Siva Rama Prasad Kambhampati, Ivelina Gueorguieva, David S. Hong - Cancer Chemotherapy and Pharmacology 2017 被引用: 101

  23. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

    著者: Dirk B. Mendel, Alexander Laird, Xiaohua Xin, Sharianne G. Louie, James G. Christensen, Guangmin Li, Randall Schreck, Tinya J. Abrams, Theresa J. Ngai, Leslie B. Lee, Lesley Murray, Jeremy Carver, Emily Chan, Katherine G. Moss, Joshua Haznedar, Juthamas Sukbuntherng, Robert A. Blake, Li Sun, Cho Tang, Todd Miller, Sheri Shirazian, Gerald McMahon, Julie M. Cherrington - 2003 被引用: 1,973

  24. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

    著者: Van K. Morris, Mohamed E. Salem, Halla Nimeiri, Syma Iqbal, Preet Paul Singh, Kristen K. Ciombor, Blasé N. Polite, Dustin A. Deming, Emily Chan, James L. Wade, Lianchun Xiao, Tanios Bekaii‐Saab, Luis M. Vence, Jorge Blando, Armeen Mahvash, Wai Chin Foo, Chimela Ohaji, Manolo Pasia, Gail L. Bland, Aki Ohinata, Jane E. Rogers, Amir Mehdizadeh, Kimberly C. Banks, Richard B. Lanman, Robert A. Wolff, Howard Streicher, James P. Allison, Padmanee Sharma, Cathy Eng - The Lancet Oncology 2017 被引用: 393